Search results: Sage Journals

Open accessResearch articleFirst published October, 2024

Understanding Australian Pharmacists’ Perceptions on the Utilisation of Oral 5-HT3 Antagonists as Pharmacist-Only Anti-Emetics in Comparison to Oral D2 Antagonists

Aiden Hendry, Jack Janetzki, Wern Chern Chai

Journal of Pharmacy Practice

Restricted accessResearch articleFirst published December, 2012

Effectiveness of Palonosetron Versus Other Serotonin 5-HT3 Receptor Antagonists in Triple Antiemetic Regimens During Multiday Highly Emetogenic Chemotherapy

Kyung Im Kim, Dong Eun Lee, Inhye Cho [...]

Annals of Pharmacotherapy

Restricted accessResearch articleFirst published August, 2006

Cilansetron: A New Selective Serotonin Type 3 (5-HT3)-Receptor Antagonist for the Treatment of Irritable Bowel Syndrome in Males and Females

Brent A. Albertson

Hospital Pharmacy

Open accessResearch articleFirst published December, 2016

5-HT3 receptor antagonists for the prevention of postoperative shivering: a meta-analysis

Chengmao Zhou, Yu Zhu, Zhen Liu [...]

Journal of International Medical Research

Restricted accessResearch articleFirst published September, 2017

Economic evaluation of 5-HT3 receptor antagonists in combination with dexamethasone for the prevention of ‘overall’ nausea and vomiting following highly emetogenic chemotherapy in Chinese adult patients

Qiong Du, Qing Zhai, Bin Zhu [...]

Journal of Oncology Pharmacy Practice

Restricted accessResearch articleFirst published December, 1990

Prevention of Nausea and Vomiting in Cisplatin-Treated Patients by a Selective 5-Hydroxytryptamine (5-HT3) Receptor Antagonist,ICS 205-930

Luigi Dogliotti, Roberto Faggiuolo, Alfredo Berruti [...]

Tumori Journal

Restricted accessCase reportFirst published June, 2012

Possible anaphylaxis to palonoestron

John M Pietkiewicz

Journal of Oncology Pharmacy Practice

Restricted accessOtherFirst published January, 2004

Cancer Patients Submitted to Innovative Chemotherapeutic Agents of Intermediate Emetogenic Potential: Antiemetic Prescriptions and Incidence of Emesis

Verena De Angelis

Tumori Journal

Restricted accessResearch articleFirst published September, 2000

A review of dolasetron as management of nausea and vomiting in cancer patients

Amy W. Valley

Journal of Oncology Pharmacy Practice

Restricted accessResearch articleFirst published August, 2023

Huo Xiang Zheng Qi Oral Liquid Combined with 5-HT3 Receptor Antagonists and Dexamethasone Can Prevent Chemotherapy-Induced Nausea and Vomiting for Patients Receiving Multiday Cisplatin-Based Regimen: A Multicenter Trial

Hao Wei, Yu Sun, Lingling Xie [...]

Journal of Integrative and Complementary Medicine

Open accessResearch articleFirst published October, 2024

Understanding Australian Pharmacists’ Perceptions on the Utilisation of Oral 5-HT3 Antagonists as Pharmacist-Only Anti-Emetics in Comparison to Oral D2 Antagonists

Aiden Hendry, Jack Janetzki, Wern Chern Chai

Journal of Pharmacy Practice

Restricted accessResearch articleFirst published December, 2012

Effectiveness of Palonosetron Versus Other Serotonin 5-HT3 Receptor Antagonists in Triple Antiemetic Regimens During Multiday Highly Emetogenic Chemotherapy

Kyung Im Kim, Dong Eun Lee, Inhye Cho [...]

Annals of Pharmacotherapy

Restricted accessResearch articleFirst published August, 2006

Cilansetron: A New Selective Serotonin Type 3 (5-HT3)-Receptor Antagonist for the Treatment of Irritable Bowel Syndrome in Males and Females

Brent A. Albertson

Hospital Pharmacy

Open accessResearch articleFirst published December, 2016

5-HT3 receptor antagonists for the prevention of postoperative shivering: a meta-analysis

Chengmao Zhou, Yu Zhu, Zhen Liu [...]

Journal of International Medical Research

Restricted accessResearch articleFirst published September, 2017

Economic evaluation of 5-HT3 receptor antagonists in combination with dexamethasone for the prevention of ‘overall’ nausea and vomiting following highly emetogenic chemotherapy in Chinese adult patients

Qiong Du, Qing Zhai, Bin Zhu [...]

Journal of Oncology Pharmacy Practice

Restricted accessResearch articleFirst published December, 1990

Prevention of Nausea and Vomiting in Cisplatin-Treated Patients by a Selective 5-Hydroxytryptamine (5-HT3) Receptor Antagonist,ICS 205-930

Luigi Dogliotti, Roberto Faggiuolo, Alfredo Berruti [...]

Tumori Journal

Restricted accessCase reportFirst published June, 2012

Possible anaphylaxis to palonoestron

John M Pietkiewicz

Journal of Oncology Pharmacy Practice

Restricted accessOtherFirst published January, 2004

Cancer Patients Submitted to Innovative Chemotherapeutic Agents of Intermediate Emetogenic Potential: Antiemetic Prescriptions and Incidence of Emesis

Verena De Angelis

Tumori Journal

Restricted accessResearch articleFirst published September, 2000

A review of dolasetron as management of nausea and vomiting in cancer patients

Amy W. Valley

Journal of Oncology Pharmacy Practice

Restricted accessResearch articleFirst published August, 2023

Huo Xiang Zheng Qi Oral Liquid Combined with 5-HT3 Receptor Antagonists and Dexamethasone Can Prevent Chemotherapy-Induced Nausea and Vomiting for Patients Receiving Multiday Cisplatin-Based Regimen: A Multicenter Trial

Hao Wei, Yu Sun, Lingling Xie [...]

Journal of Integrative and Complementary Medicine